A biotech company is moving forward with human trials of an experimental antiviral drug that could treat three serious viral diseases for which no approved medications currently exist: monkeypox, measles, and smallpox. NanoViricides, Inc. announced that its drug candidate NV-387 has received regulatory approval to begin Phase II clinical trials in the Democratic Republic of Congo, marking a significant step toward addressing critical gaps in pandemic preparedness.

What Makes NV-387 Different From Existing Antivirals?

Unlike traditional antiviral drugs that target specific viral proteins, NV-387 works by mimicking the attachment receptors that viruses need to infect human cells. This approach offers a fundamental advantage: viruses cannot easily evolve resistance to it. According to the company's regulatory filings, the drug mimics critical features of conserved attachment receptors that over 90 percent of viruses use to cause infection and spread between people. Because viruses would need to change how they fundamentally attach to cells, they cannot escape this drug through simple genetic mutations.

In laboratory and animal studies, NV-387 has demonstrated broad-spectrum activity against multiple serious viruses. Researchers found that the drug could cure lethal respiratory syncytial virus (RSV) infection in mice, outperformed existing flu medications like Tamiflu and Xofluza against H3N2 influenza, and proved highly effective in animal models of monkeypox and smallpox.

Why Is There Such an Urgent Need for These Treatments?

The gap in available treatments for these three diseases is striking. Measles and monkeypox currently have no FDA-approved medications, leaving patients with supportive care as their only option. For smallpox, the two drugs stockpiled in the U.S. Strategic National Stockpile have significant limitations. One drug can be defeated by a single genetic mutation in the virus, while the other requires physician-supervised treatment, making it impractical for rapid response to a bioterrorism scenario.

Monkeypox presents a particularly complex challenge. Two drugs approved under the FDA's Animal Rule, tecovirimat and brincidofovir, have shown disappointing results. Tecovirimat failed to demonstrate effectiveness over standard care in clinical trials, while brincidofovir carries a black box warning for liver toxicity. The Jynneos vaccine, while FDA-approved for both smallpox and monkeypox, has limited effectiveness. Real-world data shows the two-dose vaccine provides only 66.6 percent protection against disease progression in HIV-negative individuals and just 44.8 percent in HIV-positive individuals for monkeypox Clade II, the less severe form circulating in Western countries.

How Is NV-387 Being Developed?

NanoViricides has adopted an "orphan-first" development strategy, focusing on rare diseases to accelerate regulatory approval. The company has filed for orphan drug designation with the U.S. Food and Drug Administration (FDA) for three conditions: measles, monkeypox, and smallpox. If granted, these designations provide significant advantages, including more frequent communication with the FDA, an additional seven years of market exclusivity after approval, research and development tax benefits, and waiver of certain FDA fees.

The company has already received orphan drug designation for NV-387 for measles treatment as of late April 2026. It has also applied for rare pediatric disease drug designation for measles, which could unlock a priority review voucher upon FDA approval. These vouchers are tradable instruments; a recent sale of such a voucher brought $180 million, representing a potential revenue opportunity even before the drug reaches commercial markets.

Steps to Understanding NV-387's Development Path

• Phase II Clinical Trial: The company is preparing to launch a Phase II trial in the Democratic Republic of Congo to evaluate NV-387's safety and effectiveness for monkeypox treatment, with local regulatory approval already obtained.
• Orphan Drug Designations: NanoViricides has filed for FDA orphan drug status for measles, monkeypox, and smallpox, which accelerates development timelines and provides market exclusivity incentives.
• Regulatory Incentives: Orphan drug designation provides seven additional years of market exclusivity, tax benefits, FDA fee waivers, and more frequent regulatory communication compared to standard drug development.
• Future Development Plans: The company intends to advance NV-387 for both treatment and prevention of measles in the United States, with plans to seek non-dilutive government funding.

What Are the Challenges Ahead?

While the scientific promise is significant, the company faces a substantial funding challenge. As of March 31, 2026, NanoViricides reported approximately $3.38 million in cash and cash equivalents, with total assets of about $10.20 million. The company indicated it does not have sufficient funding to continue operations through May 2027 for its planned objectives, which include the Phase II monkeypox trial and additional clinical development. This funding gap will likely require the company to secure additional investment or grants to move forward with human trials.

The monkeypox situation in Africa adds urgency to the development timeline. Monkeypox Clade I, the more severe form, is endemic in the African region and affects entire populations, including children. In contrast, monkeypox Clade II, the less severe form, has become endemic in Western countries, where transmission occurs primarily among men who have sex with men. Vaccine deployment logistics and costs remain major obstacles in developing countries, making an effective oral or injectable treatment particularly valuable for regions with limited healthcare infrastructure.

The poxvirus family itself represents one of the most biologically complex groups of DNA viruses known. Unlike most DNA viruses that replicate within the cell nucleus, poxviruses carry out their entire replication cycle in the cytoplasm, requiring an unusually complex viral genome. This complexity underscores why developing broad-spectrum treatments has proven so challenging and why NV-387's novel mechanism represents a potentially important advance.

If Phase II trials demonstrate safety and effectiveness, NV-387 could address a critical gap in pandemic preparedness and provide treatment options for diseases that currently leave patients with limited medical options. The coming months will be crucial as the company works to secure funding and establish clinical trial sites in Central Africa.

" }